A MIT study on clinical trial success rates found that the overall probability of success for all drugs and vaccines is 13.8 percent. Two-thirds of trial failures occur due to inadequate efficiency, flawed design, inappropriate end points, or under-enrolment.
While many professionals are aware of the use of Artificial Intelligence (AI) to support clinical data analytics, the full range of its potential is less well known. AI has the potential to transform many of the key steps in clinical trials, from protocol design to study execution, reduce the cost of conducting clinical trials and increase the probability of studies’ success. AI can also help enterprise and mid-market sponsors, as well contract research organizations (CROs), analyse and develop strategies from vast amounts of historical data, which can also be a good database for future trials but an impossible manual task.